Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

CONCLUSION: Single-agent nanomolecular liposomal annamycin appears to be well tolerated, and shows evidence of clinical activity as a single agent in refractory adult ALL.
PMID: 23763920 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM Tags: Clin Lymphoma Myeloma Leuk Source Type: research